[RSS OUTLETS]score: 0.42

OpenAI researcher Miles Wang pursuing $2B valuation for AI drug discovery startup

July 14, 2026

OpenAI researcher Miles Wang is in discussions to launch a new venture focused on applying artificial intelligence to life sciences. The startup aims for a $2 billion valuation based on current investor interest in AI-driven pharmaceutical breakthroughs.

HOW THIS AFFECTS YOU

●

founderWatch this space for a new high-capital competitor in the biotech sector.

●

investorThe $2B valuation target signals high market appetite for AI-driven drug discovery.

●

healthAI-driven life sciences startups are moving toward massive enterprise valuations.

read original ↗techcrunch.com

DAILY DIGEST

you don't check 9 sources — we do. one email every morning, read in 2 min. free. unsubscribe anytime. privacy

← back to feed